EMAIL THIS PAGE TO A FRIEND

Molecular medicine (Cambridge, Mass.)

Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.


PMID 26023849

Abstract

Mammalian target of rapamycin (mTOR) and phosphatidylinositol 3-kinase (PI3K) are two key components of PI3K/Akt/mTOR signaling pathway. Dysregulation of these pathways have been found in many cancers, including epithelial ovarian cancer (EOC), however, the role of mTOR has not been fully elucidated in Middle Eastern EOC. Therefore, we investigated the activation of mTOR complexes (mTORC1 and mTORC2) in a cohort of 156 EOC from Saudi Arabia by immunohistochemistry in a tissue microarray format. mTORC1 and mTORC2 were found to be activated in 55 of 146 (37.7%) and 63 of 140 (45%) of EOC samples, respectively. mTORC1 was significantly associated with mTORC2 (p < 0.0001) activation and both mTOR complexes were significantly associated with p-AKT (p = 0.0205 and 0.0298) and p-P70S6 (p < 0.0001 and 0.0035), respectively. Interestingly, mTOR activation incurred a poor progression-free survival (PFS) (p = 0.0188) in EOC. Next, the in vitro effect of inactivation of mTOR complexes was evaluated using a second-generation mTOR inhibitor, Torin2, on a panel of EOC cell lines. Torin2 treatment decreased cell viability and induced apoptosis in a dose-dependent manner via inactivation of mTORC1 and mTORC2 and their downstream targets in EOC cell lines. Furthermore, treatment of EOC cells with a subtoxic dose of Torin2 potentiated a cisplatin-induced apoptotic response in EOC cell lines. Finally, we studied the in vivo effect of a combination of Torin2 and cisplatin and found that this combination synergistically inhibited tumor growth in nude mice. These studies highlight the importance of targeting the mTOR survival pathway and suggest that cotreatment with cisplatin and Torin2 may be beneficial for the management of EOC.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA005513
Anti-BIRC2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1401012
Anti-BIRC2 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2501559
Anti-BIRC3 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2501560
Anti-BIRC3 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1409216
Anti-BIRC3 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA002317
Anti-BIRC3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1401013
Anti-BIRC3 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1405469
Anti-BIRC4 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1411890
ANTI-BIRC4 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
X4503 Anti-XIAP antibody produced in goat, affinity isolated antibody, lyophilized powder
PRS3331
Anti-XIAP antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4501453
Anti-XIAP antibody produced in rabbit, affinity isolated antibody
SAB4100427
Monoclonal Anti-BIRC3 antibody produced in mouse, clone BIRC3-A359, culture supernatant
WH0000331M1
Monoclonal Anti-BIRC4 antibody produced in mouse, clone 2B3, purified immunoglobulin, buffered aqueous solution
SAB1403557
Monoclonal Anti-BIRC4 antibody produced in mouse, clone 1F4, purified immunoglobulin, buffered aqueous solution